UK markets closed

Kinarus Therapeutics Holding AG (0QNS.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
0.0400+0.0400 (+84.00%)
At close: 04:33PM BST

Kinarus Therapeutics Holding AG

3, Avenue de Florimont
Lausanne 1006
Switzerland

https://www.kinarus.com

Sector(s)
Industry
Full-time employees

Description

Perfect Holding SA, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 MAPK inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company is based in Lausanne, Switzerland.

Corporate governance

Kinarus Therapeutics Holding AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.